870 related articles for article (PubMed ID: 26166730)
1. GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson's disease.
Hoban DB; Howard L; Dowd E
Neuroscience; 2015 Sep; 303():402-11. PubMed ID: 26166730
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease.
Ericson C; Georgievska B; Lundberg C
Eur J Neurosci; 2005 Dec; 22(11):2755-64. PubMed ID: 16324109
[TBL] [Abstract][Full Text] [Related]
3. Potential of rat bone marrow-derived mesenchymal stem cells as vehicles for delivery of neurotrophins to the Parkinsonian rat brain.
Moloney TC; Rooney GE; Barry FP; Howard L; Dowd E
Brain Res; 2010 Nov; 1359():33-43. PubMed ID: 20732313
[TBL] [Abstract][Full Text] [Related]
4. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
[TBL] [Abstract][Full Text] [Related]
5. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
[TBL] [Abstract][Full Text] [Related]
6. Glial cell line-derived neurotrophic factor-secreting genetically modified human bone marrow-derived mesenchymal stem cells promote recovery in a rat model of Parkinson's disease.
Glavaski-Joksimovic A; Virag T; Mangatu TA; McGrogan M; Wang XS; Bohn MC
J Neurosci Res; 2010 Sep; 88(12):2669-81. PubMed ID: 20544825
[TBL] [Abstract][Full Text] [Related]
7. Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease.
Andereggen L; Meyer M; Guzman R; Ducray AD; Widmer HR
Brain Res; 2009 Jun; 1276():39-49. PubMed ID: 19389387
[TBL] [Abstract][Full Text] [Related]
8. The effect of lentivirus-mediated TH and GDNF genetic engineering mesenchymal stem cells on Parkinson's disease rat model.
Shi D; Chen G; Lv L; Li L; Wei D; Gu P; Gao J; Miao Y; Hu W
Neurol Sci; 2011 Feb; 32(1):41-51. PubMed ID: 20706756
[TBL] [Abstract][Full Text] [Related]
9. The reduction in immunogenicity of neurotrophin overexpressing stem cells after intra-striatal transplantation by encapsulation in an in situ gelling collagen hydrogel.
Hoban DB; Newland B; Moloney TC; Howard L; Pandit A; Dowd E
Biomaterials; 2013 Dec; 34(37):9420-9. PubMed ID: 24054846
[TBL] [Abstract][Full Text] [Related]
10. Priming Wharton's jelly-derived mesenchymal stromal/stem cells with ROCK inhibitor improves recovery in an intracerebral hemorrhage model.
Lee HS; Kim KS; Lim HS; Choi M; Kim HK; Ahn HY; Shin JC; Joe YA
J Cell Biochem; 2015 Feb; 116(2):310-9. PubMed ID: 25185536
[TBL] [Abstract][Full Text] [Related]
11. Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat.
Hoban DB; Connaughton E; Connaughton C; Hogan G; Thornton C; Mulcahy P; Moloney TC; Dowd E
Brain Behav Immun; 2013 Jan; 27(1):91-100. PubMed ID: 23044176
[TBL] [Abstract][Full Text] [Related]
12. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat.
Blandini F; Cova L; Armentero MT; Zennaro E; Levandis G; Bossolasco P; Calzarossa C; Mellone M; Giuseppe B; Deliliers GL; Polli E; Nappi G; Silani V
Cell Transplant; 2010; 19(2):203-17. PubMed ID: 19906332
[TBL] [Abstract][Full Text] [Related]
13. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
14. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
Cunningham LA; Su C
Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664
[TBL] [Abstract][Full Text] [Related]
15. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
[TBL] [Abstract][Full Text] [Related]
16. Promotion of survival and regeneration of nigral dopamine neurons in a rat model of Parkinson's disease after implantation of embryonal carcinoma-derived neurons genetically engineered to produce glial cell line-derived neurotrophic factor.
Nakao N; Yokote H; Nakai K; Itakura T
J Neurosurg; 2000 Apr; 92(4):659-70. PubMed ID: 10761657
[TBL] [Abstract][Full Text] [Related]
17. 6-Hydroxydopamine induces distinct alterations in GDF5 and GDNF mRNA expression in the rat nigrostriatal system in vivo.
Gavin AM; Walsh S; Wyatt S; O'Keeffe GW; Sullivan AM
Neurosci Lett; 2014 Feb; 561():176-81. PubMed ID: 24373993
[TBL] [Abstract][Full Text] [Related]
18. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
Rosenblad C; Kirik D; Björklund A
Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
[TBL] [Abstract][Full Text] [Related]
19. Intravenous administration of glial cell line-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in the adult rat.
Horita Y; Honmou O; Harada K; Houkin K; Hamada H; Kocsis JD
J Neurosci Res; 2006 Nov; 84(7):1495-504. PubMed ID: 16998918
[TBL] [Abstract][Full Text] [Related]
20. Effects of striatal transplantation of cells transfected with GDNF gene without pre- and pro-regions in mouse model of Parkinson's disease.
Revishchin A; Moiseenko L; Kust N; Bazhenova N; Teslia P; Panteleev D; Kovalzon V; Pavlova G
BMC Neurosci; 2016 Jun; 17(1):34. PubMed ID: 27286696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
